Literature DB >> 7781140

Safety and efficacy of intraperitoneal injection of etoposide in oil suspension in mice with peritoneal carcinomatosis.

J S Lee1, T Takahashi, A Hagiwara, C Yoneyama, M Itoh, T Sasabe, S Muranishi, S Tashima.   

Abstract

We compared the safety and efficacy in mice with peritoneal carcinomatosis of two etoposide formulations: an aqueous solution (Etp-sol) and particles suspended in oil (the addition products of iodine and the ethyl esters of the fatty acids obtained from poppy-seed oil (Lipiodol) or sesame oil; Etp-oil). We also investigated tissue distribution of etoposide in rats treated with Etp-oil and Etp-sol. Etoposide was injected intraperitoneally at concentrations ranging from 52 to 392 mg/kg (increasing geometrically by a factor of 1.4). The 50% lethal dose (LD50), determined over a 2-week period of observation, was 135 mg/kg for Etp-oil and 108 mg/kg for Etp-sol. Autopsy findings included macroscopic intestinal bleeding, necrosis of the intestinal mucosa, and pulmonary congestion in mice from both treatment groups. In the efficacy trials. 10(6) P388 leukemia cells were transplanted into CDF1 male mice, and Etp-oil and Etp-sol were injected at doses of 20 mg/kg and 80 mg/kg. In the groups receiving the 20 mg/kg dose, 11 of 19 mice in the Etp-oil group survived to day 60 compared with 3 of 20 mice in the Etp-sol group. Toxicity-related deaths occurred in 1 of 20 mice treated with 80 mg/kg Etp-oil and in 8 of 20 mice treated with 80 mg/kg Etp-sol. No cancer-related deaths were associated with the 80 mg/kg dose in either treatment group. Our findings showed that the Etp-oil was associated with a lower toxicity and a higher efficacy than the Etp-sol. To evaluate tissue distribution, rats were injected intraperitoneally with 5 mg/kg body weight of Etp-sol or Etp-oil. The tissue distribution of etoposide was subsequently analyzed by high performance liquid chromatography. Compared with Etp-sol, Etp-oil delivered significantly greater amounts of etoposide and for a longer period to the omentum, taken as representative of the intraperitoneal tissue, and the etoposide concentration in blood plasma was increased more slowly and decreased more gradually.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7781140     DOI: 10.1007/BF00685848

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  19 in total

1.  Phase II clinical trial of weekly administration of VP-16-213 in small cell bronchogenic carcinoma.

Authors:  M H Cohen; L E Broder; B E Fossieck; D C Ihde; J D Minna
Journal:  Cancer Treat Rep       Date:  1977 May-Jun

2.  VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules.

Authors:  F Cavalli; R W Sonntag; F Jungi; H J Senn; K W Brunner
Journal:  Cancer Treat Rep       Date:  1978-03

Review 3.  VP16-213 (etoposide). A critical review of its activity.

Authors:  F Cavalli
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

4.  Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.

Authors:  R L Dedrick; C E Myers; P M Bungay; V T DeVita
Journal:  Cancer Treat Rep       Date:  1978-01

5.  Infusion of high doses of undiluted etoposide through central venous catheters during preparation for bone marrow transplantation.

Authors:  R J Creger; R M Fox; H M Lazarus
Journal:  Cancer Invest       Date:  1990       Impact factor: 2.176

Review 6.  The podophyllotoxin derivatives VP16-213 and VM26.

Authors:  B F Issell
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

7.  Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy.

Authors:  G Los; P H Mutsaers; W J van der Vijgh; G S Baldew; P W de Graaf; J G McVie
Journal:  Cancer Res       Date:  1989-06-15       Impact factor: 12.701

Review 8.  Etoposide (VP-16-213).

Authors:  B F Issell; S T Crooke
Journal:  Cancer Treat Rev       Date:  1979-06       Impact factor: 12.111

9.  Etoposide microcrystals suspended in oil: a new dosage form to peritoneal carcinomatosis in mice.

Authors:  A Hagiwara; T Takahashi; T Sasabe; M Ito; M Lee; C Sakakura; S Shoubayashi; S Tashima; S Muranishi
Journal:  Oncology       Date:  1992       Impact factor: 2.935

10.  [Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)].

Authors:  H J Schmoll; N Niederle; W Achterrath
Journal:  Klin Wochenschr       Date:  1981-11-02
View more
  5 in total

1.  Etoposide induces heritable chromosomal aberrations and aneuploidy during male meiosis in the mouse.

Authors:  F Marchetti; J B Bishop; X Lowe; W M Generoso; J Hozier; A J Wyrobek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-03-13       Impact factor: 11.205

2.  Tumoricidal effects of etoposide incorporated into solid lipid nanoparticles after intraperitoneal administration in Dalton's lymphoma bearing mice.

Authors:  Lakkireddy Harivardhan Reddy; Jawahar Singh Adhikari; Bilikere Srinirasa Rao Dwarakanath; Rakesh Kumar Sharma; Rayasa Ramachandra Murthy
Journal:  AAPS J       Date:  2006-04-14       Impact factor: 4.009

3.  Local drug delivery system using ceramics: vacuum method for impregnating a chemotherapeutic agent into a porous hydroxyapatite block.

Authors:  M Itokazu; M Esaki; K Yamamoto; T Tanemori; T Kasai
Journal:  J Mater Sci Mater Med       Date:  1999-04       Impact factor: 3.896

4.  Depletion of SMC5/6 sensitizes male germ cells to DNA damage.

Authors:  G Hwang; D E Verver; M A Handel; G Hamer; P W Jordan
Journal:  Mol Biol Cell       Date:  2018-10-03       Impact factor: 4.138

5.  Cereblon attenuates DNA damage-induced apoptosis by regulating the transcription-independent function of p53.

Authors:  Liang Zhou; Guoqiang Xu
Journal:  Cell Death Dis       Date:  2019-01-25       Impact factor: 8.469

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.